JP2013532660A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532660A5 JP2013532660A5 JP2013520869A JP2013520869A JP2013532660A5 JP 2013532660 A5 JP2013532660 A5 JP 2013532660A5 JP 2013520869 A JP2013520869 A JP 2013520869A JP 2013520869 A JP2013520869 A JP 2013520869A JP 2013532660 A5 JP2013532660 A5 JP 2013532660A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- alkoxy
- optionally substituted
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 100
- 125000003545 alkoxy group Chemical group 0.000 claims 44
- 229910052739 hydrogen Inorganic materials 0.000 claims 40
- 239000001257 hydrogen Substances 0.000 claims 40
- 229910052736 halogen Inorganic materials 0.000 claims 38
- 150000002367 halogens Chemical class 0.000 claims 38
- 125000001424 substituent group Chemical group 0.000 claims 36
- 150000002431 hydrogen Chemical class 0.000 claims 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 28
- 125000003342 alkenyl group Chemical group 0.000 claims 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims 26
- 125000000304 alkynyl group Chemical group 0.000 claims 24
- 125000000623 heterocyclic group Chemical group 0.000 claims 24
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 20
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- -1 stereoisomers Chemical class 0.000 claims 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 150000002148 esters Chemical class 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 125000003302 alkenyloxy group Chemical group 0.000 claims 4
- 125000005133 alkynyloxy group Chemical group 0.000 claims 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- DITZKPGGPGEQCE-UHFFFAOYSA-N azulene-5-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=CC=CC2=C1 DITZKPGGPGEQCE-UHFFFAOYSA-N 0.000 claims 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- ZMGWNKLTJQXNAB-UHFFFAOYSA-N 2h-chromene-6-carboxylic acid Chemical compound O1CC=CC2=CC(C(=O)O)=CC=C21 ZMGWNKLTJQXNAB-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- WSVSRNIYZVCNIY-UHFFFAOYSA-N 7-(benzenesulfonylmethyl)-4-methyl-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1=2C=COC=2C(C)OC(C=2C(O)=O)=C1C=CC=2CS(=O)(=O)C1=CC=CC=C1 WSVSRNIYZVCNIY-UHFFFAOYSA-N 0.000 claims 1
- ZTKSCKSNALMGMI-UHFFFAOYSA-N 7-(benzenesulfonylmethyl)-4-oxofuro[2,3-c]chromene-6-carboxylic acid Chemical compound C1=CC=2C=3C=COC=3C(=O)OC=2C(C(=O)O)=C1CS(=O)(=O)C1=CC=CC=C1 ZTKSCKSNALMGMI-UHFFFAOYSA-N 0.000 claims 1
- YATHIMWFGWBSIT-UHFFFAOYSA-N 7-(benzenesulfonylmethyl)-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1=CC=2C=3C=COC=3COC=2C(C(=O)O)=C1CS(=O)(=O)C1=CC=CC=C1 YATHIMWFGWBSIT-UHFFFAOYSA-N 0.000 claims 1
- DCYRGSMTVUUKSL-UHFFFAOYSA-N 7-(benzenesulfonylmethyl)furo[2,3-c]quinoline-6-carboxylic acid Chemical compound C1=CC2=C3C=COC3=CN=C2C(C(=O)O)=C1CS(=O)(=O)C1=CC=CC=C1 DCYRGSMTVUUKSL-UHFFFAOYSA-N 0.000 claims 1
- RFPRHKPCTLCDEC-AATRIKPKSA-N 7-[[2-[(e)-3-(diethylamino)prop-1-enyl]-4-fluorophenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical class CCN(CC)C\C=C\C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O RFPRHKPCTLCDEC-AATRIKPKSA-N 0.000 claims 1
- RFPRHKPCTLCDEC-WAYWQWQTSA-N 7-[[2-[(z)-3-(diethylamino)prop-1-enyl]-4-fluorophenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound CCN(CC)C\C=C/C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O RFPRHKPCTLCDEC-WAYWQWQTSA-N 0.000 claims 1
- CBJSPEGLDIAGBF-ARJAWSKDSA-N 7-[[2-[(z)-3-(ethylamino)prop-1-enyl]-4-fluorophenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound CCNC\C=C/C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O CBJSPEGLDIAGBF-ARJAWSKDSA-N 0.000 claims 1
- CNSPMLOZLHMVQX-UHFFFAOYSA-N 7-[[2-[3-(diethylamino)propyl]-4-fluorophenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound CCN(CC)CCCC1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O CNSPMLOZLHMVQX-UHFFFAOYSA-N 0.000 claims 1
- QNLSUCSABPHYKA-UHFFFAOYSA-N 7-[[2-[3-(diethylamino)propyl]-4-fluorophenyl]sulfonylamino]furo[2,3-c]quinoline-6-carboxylic acid Chemical compound CCN(CC)CCCC1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)C=N2)C2=C1C(O)=O QNLSUCSABPHYKA-UHFFFAOYSA-N 0.000 claims 1
- DWXHOVUMTHMVJK-UPHRSURJSA-N 7-[[4-fluoro-2-[(z)-3-(3-hydroxyazetidin-1-yl)prop-1-enyl]phenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1C(O)CN1C\C=C/C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O DWXHOVUMTHMVJK-UPHRSURJSA-N 0.000 claims 1
- TVRQUVMDOXDPBM-NLVOMGJBSA-N 7-[[4-fluoro-2-[(z)-3-[(3r)-3-hydroxypyrrolidin-1-yl]prop-1-enyl]phenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1[C@H](O)CCN1C\C=C/C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O TVRQUVMDOXDPBM-NLVOMGJBSA-N 0.000 claims 1
- TVRQUVMDOXDPBM-YYZONTRBSA-N 7-[[4-fluoro-2-[(z)-3-[(3s)-3-hydroxypyrrolidin-1-yl]prop-1-enyl]phenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1[C@@H](O)CCN1C\C=C/C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O TVRQUVMDOXDPBM-YYZONTRBSA-N 0.000 claims 1
- ISTCDIQUYWIORV-UPHRSURJSA-N 7-[[4-fluoro-2-[(z)-3-morpholin-4-ylprop-1-enyl]phenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1=CC=2C=3C=COC=3COC=2C(C(=O)O)=C1NS(=O)(=O)C1=CC=C(F)C=C1\C=C/CN1CCOCC1 ISTCDIQUYWIORV-UPHRSURJSA-N 0.000 claims 1
- WTWWMQFXEKRNCA-ARJAWSKDSA-N 7-[[4-fluoro-2-[(z)-3-pyrrolidin-1-ylprop-1-enyl]phenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1=CC=2C=3C=COC=3COC=2C(C(=O)O)=C1NS(=O)(=O)C1=CC=C(F)C=C1\C=C/CN1CCCC1 WTWWMQFXEKRNCA-ARJAWSKDSA-N 0.000 claims 1
- BRPFFWNUJBVZEB-UHFFFAOYSA-N 8-(benzenesulfonylmethyl)-4,5-dihydrofuro[2,3-d][1]benzoxepine-7-carboxylic acid Chemical compound C1=CC=2C=3C=COC=3CCOC=2C(C(=O)O)=C1CS(=O)(=O)C1=CC=CC=C1 BRPFFWNUJBVZEB-UHFFFAOYSA-N 0.000 claims 1
- 239000005973 Carvone Substances 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102000002933 Thioredoxin Human genes 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940094937 thioredoxin Drugs 0.000 claims 1
- 108060008226 thioredoxin Proteins 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36665010P | 2010-07-22 | 2010-07-22 | |
| US61/366,650 | 2010-07-22 | ||
| US201161470093P | 2011-03-31 | 2011-03-31 | |
| US61/470,093 | 2011-03-31 | ||
| PCT/US2011/044864 WO2012012642A1 (en) | 2010-07-22 | 2011-07-21 | Tricyclic compounds and methds of making and using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532660A JP2013532660A (ja) | 2013-08-19 |
| JP2013532660A5 true JP2013532660A5 (OSRAM) | 2014-09-11 |
| JP5913310B2 JP5913310B2 (ja) | 2016-04-27 |
Family
ID=44504203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520869A Active JP5913310B2 (ja) | 2010-07-22 | 2011-07-21 | 三環式化合物ならびにその作製および使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9266896B2 (OSRAM) |
| EP (1) | EP2595988B1 (OSRAM) |
| JP (1) | JP5913310B2 (OSRAM) |
| KR (1) | KR20130043207A (OSRAM) |
| CN (1) | CN103249735B (OSRAM) |
| AU (1) | AU2011281037B2 (OSRAM) |
| BR (1) | BR112013001613A2 (OSRAM) |
| CA (1) | CA2806221A1 (OSRAM) |
| MX (1) | MX2013000836A (OSRAM) |
| WO (1) | WO2012012642A1 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
| MX337575B (es) | 2009-10-09 | 2016-03-10 | Zafgen Corp | Compuestos de sulfona y métodos para lafabricación y uso de éstos. |
| US8772333B2 (en) | 2010-01-08 | 2014-07-08 | Zafgen, Inc. | Fumigillol type compounds and methods of making and using same |
| WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
| WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| WO2012012642A1 (en) | 2010-07-22 | 2012-01-26 | Zafgen Corporation | Tricyclic compounds and methds of making and using same |
| WO2012051318A1 (en) | 2010-10-12 | 2012-04-19 | Zafgen Corporation | Sulphonamide compounds and methods of making and using same |
| BR112013013411A2 (pt) | 2010-11-29 | 2016-09-13 | Zafgen Inc | tratamento de obesidade usando administração não diária de 6-0-(4-dimetilaminoetxi) cinamoil fumagilol |
| CN103402989B (zh) | 2011-01-26 | 2016-04-06 | 扎夫根股份有限公司 | 四唑化合物及其制备和使用方法 |
| EP2683706B1 (en) | 2011-03-08 | 2018-02-21 | Zafgen, Inc. | Oxaspiro [2.5]octane derivatives and analogs |
| BR112013028665A2 (pt) | 2011-05-06 | 2016-09-06 | Zafgen Inc | compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
| KR20140040739A (ko) * | 2011-05-06 | 2014-04-03 | 자프겐 인크. | 삼환식 피라졸 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
| WO2012154676A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Partially saturated tricyclic compounds and methods of making and using same |
| EP2763671A2 (en) | 2011-10-03 | 2014-08-13 | Zafgen, Inc. | Methods of treating age related disorders |
| BR112014017780A8 (pt) * | 2012-01-18 | 2017-07-11 | Zafgen Inc | Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos |
| MX2014008706A (es) * | 2012-01-18 | 2015-03-05 | Zafgen Inc | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. |
| EP2846792B1 (en) | 2012-05-08 | 2018-08-15 | Zafgen, Inc. | Treating hypothalamic obesity with metap2 inhibitors |
| JP6177888B2 (ja) | 2012-05-09 | 2017-08-09 | ザフゲン，インコーポレイテッド | フマギロール型化合物ならびにその製造および使用方法 |
| US9868717B2 (en) | 2012-11-05 | 2018-01-16 | Zafgen, Inc. | Tricyclic sulphonamide compounds and methods of making and using same |
| WO2014071363A1 (en) * | 2012-11-05 | 2014-05-08 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| JP6169716B2 (ja) * | 2012-11-05 | 2017-07-26 | ザフゲン，インコーポレイテッド | 肝疾患を治療する方法 |
| US9597309B2 (en) | 2013-03-14 | 2017-03-21 | Zafgen, Inc. | Methods of treating renal disease and other disorders |
| CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
| AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
| US11066812B2 (en) | 2017-08-07 | 2021-07-20 | Hensley Industries, Inc. | Bucket lip stabilizer structure |
| WO2019173646A1 (en) * | 2018-03-08 | 2019-09-12 | Exxonmobil Research And Engineering Company | Spirocentric compounds and polymers thereof |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4920132A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US5164410A (en) | 1988-01-09 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| KR0138530B1 (ko) | 1988-09-01 | 1998-05-15 | 우메모또 요시마사 | 푸마길롤 유도체 |
| US5180738A (en) | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
| US5288722A (en) | 1989-03-06 | 1994-02-22 | Takeda Chemical Industries, Ltd. | 6-amino-6-desoxyfumagillols, production and use thereof |
| DE69001187T2 (de) | 1989-03-06 | 1993-07-08 | Takeda Chemical Industries Ltd | 6-epifumagillole, ihre herstellung und ihre verwendung. |
| US5290807A (en) | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
| US6017954A (en) | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
| EP0415294A3 (en) | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
| TW282399B (OSRAM) | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
| US5238950A (en) | 1991-12-17 | 1993-08-24 | Schering Corporation | Inhibitors of platelet-derived growth factor |
| DE69330690T2 (de) | 1992-01-30 | 2002-06-20 | Takeda Chemical Industries, Ltd. | Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe |
| DE69311278T2 (de) | 1992-12-16 | 1997-10-30 | Takeda Chemical Industries Ltd | Stabile pharmazeutische Zubereitung mit Fumagillolderivaten |
| HU224028B1 (hu) | 1995-03-27 | 2005-05-30 | Assistance Publique-Hopitaux De Paris | Fumagillol és származékai alkalmazása bélfertőzések kezelésére szolgáló gyógyszerek előállítására |
| WO1997005131A1 (en) | 1995-08-02 | 1997-02-13 | J. Uriach & Cia. S.A. | New carboxamides with antifungal activity |
| WO1997013509A1 (en) | 1995-10-11 | 1997-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Vascular permeation inhibitor |
| EP0799616A1 (en) | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
| WO1998005293A2 (en) | 1996-08-02 | 1998-02-12 | The Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
| US6281245B1 (en) | 1996-10-28 | 2001-08-28 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
| DK0973392T3 (da) | 1997-03-04 | 2004-03-29 | Monsanto Co | Divalente sulfonyl-aryl eller heteroarylhydroxamsyreforbindelser |
| US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
| US6207704B1 (en) | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
| JP2002502814A (ja) | 1997-10-31 | 2002-01-29 | チルドレンズ・メディカル・センター・コーポレイション | 血管化した正常組織の大きさおよび増殖の調節のための方法 |
| WO1999032433A1 (en) | 1997-12-23 | 1999-07-01 | Warner-Lambert Company | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
| US6242494B1 (en) | 1998-05-01 | 2001-06-05 | Abbott Laboratories | Substituted β-amino acid inhibitors of methionine aminopeptidase-2 |
| KR100357541B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 |
| KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| JP2000116337A (ja) | 1998-10-09 | 2000-04-25 | Nippon Shokuhin Kako Co Ltd | ペットフード |
| US6392099B1 (en) | 1998-11-19 | 2002-05-21 | Eagleview Technologies, Inc. | Method and apparatus for the preparation of ketones |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| EE200100558A (et) | 1999-04-28 | 2002-12-16 | Aventis Pharma Deutschland Gmbh | Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine |
| EP1223932A4 (en) * | 1999-10-01 | 2003-01-15 | Smithkline Beecham Corp | COMPOUNDS AND METHODS |
| US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
| US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
| AR030631A1 (es) | 2000-09-29 | 2003-08-27 | Abbott Lab | Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| AU2002239479B2 (en) | 2000-11-01 | 2006-11-09 | Praecis Pharmaceuticals Incorporated | Peptides as Met-AP2 inhibitors |
| WO2002059124A2 (en) * | 2000-12-20 | 2002-08-01 | Bristol-Myers Squibb Company | Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists |
| JP3528968B2 (ja) * | 2000-12-28 | 2004-05-24 | 小野薬品工業株式会社 | 三環式複素環誘導体化合物およびその化合物を有効成分とする医薬 |
| US6545185B1 (en) | 2001-03-29 | 2003-04-08 | Eagleview Technologies, Inc. | Preparation of ketones from aldehydes |
| WO2002078699A1 (en) | 2001-03-29 | 2002-10-10 | Smithkline Beecham Corporation | Compounds and methods |
| US20020183242A1 (en) | 2001-04-11 | 2002-12-05 | Jack Henkin | Peptide antiangiogenic drugs |
| DE60233420D1 (de) | 2001-09-27 | 2009-10-01 | Equispharm Co Ltd | Fumagillolderivate und verfahren zu deren herstellung |
| US6803382B2 (en) | 2001-11-09 | 2004-10-12 | Galderma Research & Development, S.N.C. | Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
| US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
| KR100451485B1 (ko) | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
| US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
| US7030262B2 (en) | 2002-08-06 | 2006-04-18 | Abbott Laboratories | 3-Amino-2-hydroxyalkanoic acids and their prodrugs |
| US20040067266A1 (en) | 2002-10-07 | 2004-04-08 | Toppo Frank R. | Weight loss compound |
| US20040068012A1 (en) | 2002-10-08 | 2004-04-08 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| US20040157836A1 (en) | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
| WO2004078113A2 (en) | 2003-03-04 | 2004-09-16 | Pharmacia Corporation | Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| EA200600203A1 (ru) | 2003-08-08 | 2006-08-25 | Янссен Фармацевтика, Н. В. | Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2 |
| PE20050948A1 (es) | 2003-09-09 | 2005-12-16 | Japan Tobacco Inc | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv |
| PL1697378T3 (pl) | 2003-12-22 | 2008-04-30 | Memory Pharm Corp | Indole, 1h-indazole, 1,2-benzoizoksazole i 1,2-benzoizotiazole oraz ich wytwarzanie i zastosowania |
| US20050239878A1 (en) | 2003-12-29 | 2005-10-27 | Praecis Pharmaceuticals, Inc. | Inhibitors of methionine aminopeptidase-2 and uses thereof |
| KR100552043B1 (ko) | 2004-02-28 | 2006-02-20 | 주식회사종근당 | 푸마질롤 유도체를 포함하는 비만치료용 조성물 |
| AU2005245401A1 (en) | 2004-05-12 | 2005-12-01 | Chemocentryx | Aryl sulfonamides |
| CA2566512A1 (en) | 2004-06-14 | 2005-12-22 | F. Hoffmann-La Roche Ag | Hydroxamates, their manufacture and use as pharmaceutical agents |
| US20050288516A1 (en) | 2004-06-28 | 2005-12-29 | Warren Jack S | Use of a device or devices, such as a convergent divergent funnel mixer, to optimize the available reaction volume, the raw material feed ratios and the weight hourly space velocity in a tube reactor |
| CA2571683A1 (en) | 2004-06-30 | 2006-01-12 | Combinatorx, Incorporated | Methods and reagents for the treatment of metabolic disorders |
| US20060019967A1 (en) | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
| US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| MX2007003623A (es) | 2004-09-24 | 2007-09-11 | Johnson & Johnson | Compuestos sulfonamida. |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| JP4663733B2 (ja) | 2004-10-29 | 2011-04-06 | シェーリング コーポレイション | 抗ウイルス物質としての置換５−オキソピラゾールおよび置換［１，２，４］トリアゾール |
| JP2008528574A (ja) | 2005-01-26 | 2008-07-31 | チョン クン ダン ファーマシューティカル コープ． | フマギロール誘導体またはフマギロール誘導体の製造方法およびこれを含む医薬用組成物 |
| FR2886855B1 (fr) | 2005-06-08 | 2009-07-17 | Agronomique Inst Nat Rech | Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques |
| WO2006138475A2 (en) | 2005-06-16 | 2006-12-28 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| WO2007076348A2 (en) | 2005-12-23 | 2007-07-05 | Smithkline Beecham Corporation | Azaindole inhibitors of aurora kinases |
| EP1976495A2 (en) | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| US20080058395A1 (en) | 2006-06-30 | 2008-03-06 | Sepracor Inc. | Fused heterocyclic inhibitors of D-amino acid oxidase |
| WO2008008374A2 (en) | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Ccr2 inhibitors and methods of use thereof |
| DE102007020492A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Sulfonamid-Derivate |
| CA2690244C (en) | 2007-06-26 | 2016-08-09 | Ofra Benny-Ratsaby | Metap-2 inhibitor polymersomes for therapeutic administration |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| BRPI0820229A2 (pt) | 2007-11-28 | 2017-05-09 | A Stevenson Cheri | conjugados de análogos de fumagilina biodegradáveis biocompatíveis |
| ATE506359T1 (de) | 2007-11-30 | 2011-05-15 | Bayer Schering Pharma Ag | Heteroaryl-substituierte piperidine |
| WO2010009374A1 (en) | 2008-07-18 | 2010-01-21 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| EP2350012B1 (en) | 2008-10-06 | 2017-06-28 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders |
| WO2010048499A1 (en) | 2008-10-24 | 2010-04-29 | Wake Forest University | Platinum acridine anti-cancer compounds and methods thereof |
| WO2010065881A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| US20120010290A1 (en) | 2008-12-04 | 2012-01-12 | Vath James E | Methods of Treating an Overweight or Obese Subject |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
| MX337575B (es) | 2009-10-09 | 2016-03-10 | Zafgen Corp | Compuestos de sulfona y métodos para lafabricación y uso de éstos. |
| WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
| WO2011088055A2 (en) | 2010-01-12 | 2011-07-21 | Zafgen Corporation | Methods and compositions for treating cardiovascular disorders |
| WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| WO2011150338A1 (en) | 2010-05-27 | 2011-12-01 | Zafgen Corporation | Methods of treating obesity |
| WO2012012642A1 (en) | 2010-07-22 | 2012-01-26 | Zafgen Corporation | Tricyclic compounds and methds of making and using same |
| WO2012051318A1 (en) | 2010-10-12 | 2012-04-19 | Zafgen Corporation | Sulphonamide compounds and methods of making and using same |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| US20140073691A1 (en) | 2010-11-10 | 2014-03-13 | Zafgen, Inc. | Methods and composition for Treating Thyroid Hormone Related Disorders |
| WO2012074968A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors |
| BR112013013411A2 (pt) | 2010-11-29 | 2016-09-13 | Zafgen Inc | tratamento de obesidade usando administração não diária de 6-0-(4-dimetilaminoetxi) cinamoil fumagilol |
| US20140011870A1 (en) | 2010-11-29 | 2014-01-09 | Zafgen, Inc. | Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor |
| CN103402989B (zh) | 2011-01-26 | 2016-04-06 | 扎夫根股份有限公司 | 四唑化合物及其制备和使用方法 |
| WO2012154676A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Partially saturated tricyclic compounds and methods of making and using same |
| BR112013028665A2 (pt) | 2011-05-06 | 2016-09-06 | Zafgen Inc | compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
| KR20140040739A (ko) | 2011-05-06 | 2014-04-03 | 자프겐 인크. | 삼환식 피라졸 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
| US9090640B2 (en) | 2011-09-02 | 2015-07-28 | Ulrich Bierbach | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
-
2011
- 2011-07-21 WO PCT/US2011/044864 patent/WO2012012642A1/en not_active Ceased
- 2011-07-21 US US13/811,453 patent/US9266896B2/en not_active Expired - Fee Related
- 2011-07-21 CA CA2806221A patent/CA2806221A1/en not_active Abandoned
- 2011-07-21 JP JP2013520869A patent/JP5913310B2/ja active Active
- 2011-07-21 MX MX2013000836A patent/MX2013000836A/es active IP Right Grant
- 2011-07-21 EP EP11741370.8A patent/EP2595988B1/en active Active
- 2011-07-21 BR BR112013001613A patent/BR112013001613A2/pt not_active IP Right Cessation
- 2011-07-21 CN CN201180045319.0A patent/CN103249735B/zh not_active Expired - Fee Related
- 2011-07-21 KR KR1020137004371A patent/KR20130043207A/ko not_active Withdrawn
- 2011-07-21 AU AU2011281037A patent/AU2011281037B2/en not_active Ceased
-
2016
- 2016-01-07 US US14/990,299 patent/US9839623B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532660A5 (OSRAM) | ||
| JP2015504091A5 (OSRAM) | ||
| JP2014513139A5 (OSRAM) | ||
| JP2016513137A5 (OSRAM) | ||
| JP2007505933A5 (OSRAM) | ||
| JP2014513140A5 (OSRAM) | ||
| JP2011522866A5 (OSRAM) | ||
| NZ605528A (en) | Ip receptor agonist heterocyclic compounds | |
| HRP20180202T1 (hr) | Purinski derivati, namijenjeni upotrebi u liječenju alergijskih, upalnih i zaraznih bolesti | |
| JP2019512535A5 (OSRAM) | ||
| TN2016000090A1 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors. | |
| PH12015501878A1 (en) | Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative | |
| WO2009005674A3 (en) | Novel hiv reverse transcriptase inhibitors | |
| JP2014037426A5 (OSRAM) | ||
| TN2013000394A1 (fr) | Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine | |
| JP2013539789A5 (OSRAM) | ||
| JP2016521276A5 (OSRAM) | ||
| EA201100763A1 (ru) | Методы получения хинолиновых производных | |
| JP2016503797A5 (OSRAM) | ||
| RU2013141274A (ru) | Содержащие фосфор соединения в качестве ингибиторов протеинкиназ | |
| WO2009155527A3 (en) | Phosphatidylinositol 3 kinase inhibitors | |
| MX2010007746A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de diana de rapamicina de mamifero quinasa y fosfatidilinositol quinasa y su sintesis. | |
| WO2009013348A3 (en) | Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions | |
| WO2008125600A3 (en) | Pyrazole derivatives as p2x7 modulators | |
| NZ601077A (en) | Use of an adrenal hormone-modifying agent |